UK markets closed
NIKKEI 225
38,837.46 -85.54 (-0.22%) HANG SENG
18,444.11 +41.11 (+0.22%) CRUDE OIL
72.87 -0.38 (-0.52%) GOLD FUTURES
2,347.20 -0.20 (-0.01%) DOW
38,711.29 +140.26 (+0.36%) Bitcoin GBP
55,247.73 +1,155.95 (+2.14%)
Prothena Corporation plc (0PT.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 09:50PM CEST
| Previous close | 19.00 |
| Open | 20.20 |
| Bid | 20.60 x 10000 |
| Ask | 20.80 x 10000 |
| Day's range | 20.20 - 20.80 |
| 52-week range | 17.90 - 70.50 |
| Volume | |
| Avg. volume | 1 |
| Market cap | 1.181B |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.96 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 75.75 |
ZacksProthena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
Business WireProthena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
DUBLIN, May 28, 2024--Prothena today announced that Bristol Myers Squibb obtained the exclusive global license for PRX019 and will pay Prothena $80 million.
Simply Wall St.News Flash: Analysts Just Made A Notable Upgrade To Their Prothena Corporation plc (NASDAQ:PRTA) Forecasts
Celebrations may be in order for Prothena Corporation plc ( NASDAQ:PRTA ) shareholders, with the analysts delivering a...
© 2024 Yahoo. All rights reserved.